ESRRG and breast cancer: For example, the ERRγ inverse agonist GSK5182 has been shown to inhibit an adaptive antioxidant ERR-driven response thereby accentuating the chemotherapy-induced cytotoxic effects of paclitaxel in breast cancer cells [12].